Sei Investments Co. Raises Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

Sei Investments Co. grew its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 8.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 362,616 shares of the biopharmaceutical company’s stock after buying an additional 29,019 shares during the period. Sei Investments Co.’s holdings in Insmed were worth $25,035,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC raised its stake in Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 163 shares during the period. V Square Quantitative Management LLC increased its stake in shares of Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 248 shares in the last quarter. Spire Wealth Management bought a new stake in shares of Insmed during the 4th quarter valued at $47,000. Smartleaf Asset Management LLC lifted its stake in shares of Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC bought a new position in Insmed in the 4th quarter worth $86,000.

Insmed Price Performance

Shares of Insmed stock opened at $76.57 on Thursday. The stock has a market cap of $13.86 billion, a price-to-earnings ratio of -13.70 and a beta of 1.28. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock has a 50 day moving average price of $77.97 and a 200-day moving average price of $73.91. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Equities analysts expect that Insmed Incorporated will post -4.56 EPS for the current year.

Wall Street Analysts Forecast Growth

INSM has been the topic of a number of recent analyst reports. Bank of America raised their price target on Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a report on Thursday, March 20th. Wells Fargo & Company boosted their price target on Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a report on Wednesday, February 19th. UBS Group increased their price objective on shares of Insmed from $105.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Morgan Stanley boosted their target price on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $100.00 price target on shares of Insmed in a report on Wednesday, March 19th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and an average price target of $94.00.

Insider Activity at Insmed

In related news, insider Martina M.D. Flammer sold 6,172 shares of the business’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.64, for a total transaction of $392,786.08. Following the completion of the transaction, the insider now owns 101,549 shares in the company, valued at $6,462,578.36. The trade was a 5.73 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total value of $1,309,500.00. Following the completion of the sale, the chief executive officer now owns 384,960 shares in the company, valued at approximately $26,885,606.40. The trade was a 4.64 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 550,957 shares of company stock worth $42,992,528. Insiders own 4.60% of the company’s stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.